Aditxt Subsidiary Adimune Unveils Revolutionary Approach to Reprogramming the Immune System Through DNA Instructions.

Aditxt's subsidiary, Adimune, is working on a DNA-based therapeutic platform to reprogram the immune system and treat autoimmune diseases. The company has 96 granted and 22 pending patents and plans to submit for FDA approval in early 2026 for conditions like type 1 diabetes and stiff person syndrome. Adimune aims to revolutionize autoimmune disease treatment and tap into the projected $160 billion global autoimmune therapeutics market by 2030.

Aditxt, Inc. (NASDAQ: ADTX), a social innovation platform accelerating promising health innovations, has announced significant progress from its subsidiary, Adimune, Inc. (Adimune), which is pioneering a DNA-based therapeutic platform designed to reprogram the immune system. Adimune's intellectual property portfolio now includes 96 granted and 22 pending patents, supporting the company's strategy to address the global autoimmune therapeutics market, estimated at over $160 billion by 2030 [1].

Adimune's platform combines DNA instructions with a proprietary delivery system to reprogram the immune system, aiming to restore natural immune tolerance without chronic immunosuppression. The company's first product candidate, ADI-100, targets high-need conditions such as type 1 diabetes, psoriasis, and stiff person syndrome. Adimune plans to seek FDA submission and approval for first-in-human trials in early 2026, marking a critical milestone towards translating their vision into real solutions for patients [2].

Aditxt's ecosystem of research institutions, industry partners, and shareholders collaboratively drives their mission to 'Make Promising Innovations Possible Together.' The company operates a unique model that democratizes innovation and empowers collective progress. Aditxt's current programs focus on immune health and precision health, with plans to introduce an additional program dedicated to women's health through the proposed acquisition of Evofem [1].

The closing of the Evofem transaction is subject to several conditions, including approval by Evofem's shareholders and Aditxt raising sufficient capital to fund its obligations at closing. These obligations include cash payments of approximately $17 million for Evofem, with $15.0 million required to satisfy Evofem's senior secured noteholder [1].

Adimune's approach represents a fundamental shift in how we think about the immune system and biology in general. If successful, it has the potential to lead a new era of addressing diseases through innovative treatments that build significant long-term value. The company's robust patent portfolio and focus on a multi-billion-dollar global market position Adimune as a key player in the autoimmune therapeutics landscape [2].

References:
[1] https://www.marketscreener.com/news/aditxt-s-subsidiary-adimune-highlights-its-approach-to-reprogramming-the-immune-system-through-dna-i-ce7c50d9db8bfe2d
[2] https://www.stocktitan.net/news/ADTX/aditxt-s-subsidiary-adimune-highlights-its-approach-to-reprogramming-4e31eyijga68.html